WELLESLEY Hills, Mass., Oct. 16 -- The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-monthopen label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer’s Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg
On July 20, 2009, EPIX Pharmaceuticals, Inc. (the "Company") entered into an Assignment for the Benefit of Creditors (the "Assignment") in accordance with Massachusetts law. The purpose of the Assignment is to conclude the Company's operations and provide for an orderly liquidation of its assets. The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding. Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors. The designated assignee for the Company is Joseph F. Finn, Jr. at Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481.
The PRX-03140 program will be sold at auction on Wednesday, October 21 at 3 pm EDT. Please contact Joseph F. Finn, Jr. at 781-237-8840 if you are interested in participating in the auction.
(1) Lucy Hornstein, M.D. is a private practice physician in Valley Forge, PA. She is the author of a recently released book, “Declarations of a Dinosaur: 10 Laws I’ve Learned as a Family Doctor” by Kaplan Publishing.
SOURCE Joseph F. Finn, Jr., C.P.A.
Subscribe to our Free Newsletters!
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...
Water is essential to balance body fluids, boost brain function, improve digestion, prevent ...
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...View All